Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$7.23
+1.7%
$6.30
$3.93
$7.54
$364.59M1.55710,270 shs850,820 shs
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$12.99
+2.3%
$12.58
$8.06
$17.15
$333.38M0.442,222 shs74,167 shs
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.76
$2.23
$0.98
$3.44
$70.99M0.2627,658 shs26,529 shs
Canopy Growth Corporation stock logo
CGC
Canopy Growth
$1.27
+2.4%
$1.22
$0.77
$6.30
$297.41M0.6722.15 million shs17.13 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
+1.57%-1.66%+9.05%+10.75%+35.69%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-1.40%+0.32%+12.79%-3.71%+41.74%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
+2.33%-12.44%-5.88%+1.79%-6.88%
Canopy Growth Corporation stock logo
CGC
Canopy Growth
+2.48%-16.78%-0.80%-32.24%-80.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
4.4022 of 5 stars
3.52.00.04.52.52.51.3
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
1.5652 of 5 stars
3.61.00.00.02.00.80.0
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/AN/AN/AN/A
Canopy Growth Corporation stock logo
CGC
Canopy Growth
0.7575 of 5 stars
0.02.00.00.03.30.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
3.00
Buy$19.50169.71% Upside
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
3.13
Buy$26.00100.15% Upside
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
0.00
N/AN/AN/A
Canopy Growth Corporation stock logo
CGC
Canopy Growth
1.33
SellN/AN/A

Current Analyst Ratings Breakdown

Latest BYSI, ABEO, CGC, and BNTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
8/15/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$19.00 ➝ $20.00
8/12/2025
Canopy Growth Corporation stock logo
CGC
Canopy Growth
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
7/14/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
7/7/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
6/2/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$19.00
5/30/2025
Canopy Growth Corporation stock logo
CGC
Canopy Growth
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderweight ➝ Underweight
(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$3.50M105.93N/AN/A$3.19 per share2.27
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$80K4,262.34N/AN/A$4.68 per share2.78
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.75M40.56N/AN/A($0.44) per share-4.00
Canopy Growth Corporation stock logo
CGC
Canopy Growth
$274.92M1.11N/AN/A$1.47 per share0.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-$63.73M$0.7010.33N/AN/AN/A89.05%45.64%N/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$21.75M-$1.51N/AN/AN/AN/A-38.26%-35.71%9/25/2025 (Estimated)
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$11.12MN/A0.00N/AN/AN/AN/A11/6/2025 (Estimated)
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-$429.86M-$3.03N/AN/AN/A-155.76%-89.93%-44.24%N/A

Latest BYSI, ABEO, CGC, and BNTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-$0.39$1.71+$2.10$1.71$21.71 million$0.40 million
8/13/2025Q2 2025
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A-$0.04N/A-$0.04N/AN/A
8/8/2025Q1 2026
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-$0.15-$0.14+$0.01-$0.16$64.98 million$52.98 million
5/30/2025Q4 2025
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-$0.28-$0.94-$0.66-$1.00$71.84 million$45.30 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
N/AN/AN/AN/AN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/AN/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/A
Canopy Growth Corporation stock logo
CGC
Canopy Growth
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
0.09
6.73
4.90
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
0.01
14.80
14.80
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A
2.19
2.19
Canopy Growth Corporation stock logo
CGC
Canopy Growth
0.59
3.07
2.12

Institutional Ownership

CompanyInstitutional Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
80.56%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
52.19%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
40.29%
Canopy Growth Corporation stock logo
CGC
Canopy Growth
3.33%

Insider Ownership

CompanyInsider Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
6.90%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
1.30%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
29.31%
Canopy Growth Corporation stock logo
CGC
Canopy Growth
0.16%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
9051.28 million47.74 millionOptionable
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
2026.25 million25.91 millionNo Data
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
8040.33 million28.51 millionOptionable
Canopy Growth Corporation stock logo
CGC
Canopy Growth
3,150239.85 million239.47 millionOptionable

Recent News About These Companies

Best Canadian Cannabis Stocks in 2025
Canopy Growth (CGC) Q1 Revenue Jumps 9%
Cannabis stocks surge as Trump consider reclassifying the drug
A Preview Of Canopy Growth's Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abeona Therapeutics stock logo

Abeona Therapeutics NASDAQ:ABEO

$7.23 +0.12 (+1.69%)
Closing price 04:00 PM Eastern
Extended Trading
$7.21 -0.02 (-0.28%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Benitec Biopharma stock logo

Benitec Biopharma NASDAQ:BNTC

$12.99 +0.29 (+2.28%)
Closing price 04:00 PM Eastern
Extended Trading
$12.98 -0.01 (-0.08%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

BeyondSpring stock logo

BeyondSpring NASDAQ:BYSI

$1.76 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.74 -0.01 (-0.85%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Canopy Growth stock logo

Canopy Growth NASDAQ:CGC

$1.27 +0.03 (+2.42%)
Closing price 04:00 PM Eastern
Extended Trading
$1.30 +0.03 (+2.76%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.